Inherent limitations of Ki-67/MIB-1 immunohistochemistry also include sampling errors, leading to difficulties characterizing immunoreactive tumor cell nuclei [30], and the lack of statistically significant differences in survival between cutout values of Ki-67 [32]. This evidence concerns the gene MKI67 and neoplasm.